In May 2026, Japan’s Ministry of Health, Labour and Welfare (MHLW) added Amchepry (generic name: raguneprocel) to the national health insurance system at a price of about ¥55.3 million per patient — roughly two months after the product received conditional, time-limited approval in March. Developed by Sumitomo Pharma together with Kyoto University, Amchepry is the world’s first commercialized regenerative-medicine product derived from induced pluripotent stem (iPS) cells, and is intended to improve the motor symptoms of Parkinson’s disease.
What is Amchepry?
Amchepry is an allogeneic iPS cell–derived dopaminergic neural progenitor cell product. Rather than using a patient’s own cells, it begins with iPS cells established from a healthy donor. These are guided in the laboratory to become dopamine-producing neural progenitor cells, which are then surgically implanted into the region of the brain where dopamine neurons have been lost. The aim is to replenish the dopamine-producing cells whose loss drives Parkinson’s disease. Because the cells come from a donor line, the product can be prepared and stocked in advance, and is indicated for patients whose symptoms are inadequately controlled by existing drug therapy.
Insurance listing and price
On 13 May 2026, an MHLW advisory council approved public-insurance coverage, and Amchepry was listed at approximately ¥55,306,737 per course (about 2.4 million RMB at current rates). Under Japan’s public insurance and high-cost medical care system, most insured patients in Japan pay only a fraction of this amount out of pocket. A self-paying patient without Japanese insurance would, in principle, face the full drug cost in addition to surgical and hospitalization fees.
Clinical data and “conditional, time-limited” approval
Approval was based on an investigator-initiated phase 1/2 study at Kyoto University Hospital involving seven patients aged 50–69, followed for 24 months. Among the six patients evaluated for motor outcomes, potential clinical benefit was reported in four when off medication and five when on medication, with no major safety concerns reported in the study. Amchepry received “conditional and time-limited” approval under Japan’s regenerative-medicine framework — a pathway that allows earlier access in exchange for mandatory post-market data collection. Sumitomo Pharma has about seven years to gather further evidence before seeking full approval; the company has said it plans to complete its first commercial transplant by the end of 2026 and to treat on the order of 90–130 patients during the evaluation period.
Why Parkinson’s disease matters
Parkinson’s disease is a progressive neurodegenerative disorder caused by the loss of dopamine-producing neurons in the brain. Typical symptoms include tremor, muscle rigidity, slowed movement (bradykinesia) and postural instability; as it advances, patients gradually lose independent mobility and may develop cognitive difficulties. The condition is common worldwide and its prevalence rises with age, which is why new treatment approaches are a focus of intense global research.
What it means for regenerative medicine
As the first iPS cell–derived product to reach commercial, insured use, Amchepry is a milestone for the field that Shinya Yamanaka’s Nobel-winning iPS technology opened two decades ago. It is important to keep expectations realistic: the approval is conditional, the evidence base is still small, and the therapy is being introduced cautiously to a limited number of carefully selected patients in Japan. Even so, it demonstrates a viable path from iPS cell research to a real-world, reimbursed treatment — and Japan’s regenerative-medicine framework will be watched closely by regulators and patients around the world.
Disclaimer: This article is provided by Tsubaki Trading for general information only. It is not medical advice, a treatment recommendation, or an offer of any product or service. Amchepry is a prescription regenerative-medicine product that is conditionally approved and available only under specific conditions in Japan; decisions about care should be made together with qualified medical specialists.
References
- Sumitomo Pharma — Approval for manufacturing and marketing authorization of the allogeneic iPS cell-derived dopaminergic neural progenitor cell product AMCHEPRY in Japan (6 March 2026)
- Nature Biotechnology — World’s first two iPSC therapies in Japan
- Nikkei — iPS cell therapy priced at JPY 55.3 million; Parkinson’s treatment to be covered by public insurance (13 May 2026)
- Mix Online — Three regenerative-medicine products to be listed on 20 May; AMCHEPRY priced at JPY 55.3 million
For more on Japan’s pharmaceutical and regenerative-medicine landscape, explore the Tsubaki Journal.